Could ABIOMED, Inc. (ABMD) Lose its Strength? The Stock Reaches 52-Week High

May 17, 2018 - By Marie Mckinney

ABIOMED, Inc. (NASDAQ:ABMD) Logo

Investors sentiment decreased to 1.18 in Q4 2017. Its down 0.12, from 1.3 in 2017Q3. It dropped, as 19 investors sold ABIOMED, Inc. shares while 110 reduced holdings. 55 funds opened positions while 97 raised stakes. 36.44 million shares or 5.39% less from 38.51 million shares in 2017Q3 were reported.
Baillie Gifford & reported 0.45% in ABIOMED, Inc. (NASDAQ:ABMD). Qs Investors Ltd Liability Corp owns 1,504 shares. Alyeska Inv Grp Ltd Partnership stated it has 82,551 shares or 0.13% of all its holdings. Nordea Mngmt reported 12,887 shares. Northern Trust reported 335,357 shares. Plancorp Limited Liability stated it has 4,587 shares or 0.28% of all its holdings. Voya Management Ltd Liability Corporation reported 19,305 shares. Maryland-based Proshare Advsrs Limited Company has invested 0.01% in ABIOMED, Inc. (NASDAQ:ABMD). Ci Global Invs Inc has invested 0% in ABIOMED, Inc. (NASDAQ:ABMD). Millennium Mngmt Limited Com invested in 454,439 shares. Citigroup has 32,243 shares for 0% of their portfolio. 1832 Asset Mgmt L P has invested 0.22% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). Pennsylvania-based Biondo Invest Advsr Ltd Liability has invested 3.3% in ABIOMED, Inc. (NASDAQ:ABMD). Zacks Investment Mngmt holds 0.02% or 5,042 shares. Asset Management, Colorado-based fund reported 18,297 shares.

Since February 20, 2018, it had 0 buys, and 5 sales for $31.65 million activity. SUTTER MARTIN P had sold 21,890 shares worth $7.52 million on Tuesday, May 8. Another trade for 17,500 shares valued at $6.09 million was sold by Howley Michael G. $7.93M worth of stock was sold by BOLT WILLIAM J on Monday, May 7. On Monday, May 7 the insider PUHY DOROTHY E sold $4.70M.

The stock of ABIOMED, Inc. (NASDAQ:ABMD) hit a new 52-week high and has $411.64 target or 8.00 % above today’s $381.15 share price. The 8 months bullish chart indicates low risk for the $16.91 billion company. The 1-year high was reported on May, 17 by Barchart.com. If the $411.64 price target is reached, the company will be worth $1.35 billion more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 0.21% or $0.82 during the last trading session, reaching $381.15. About 45,706 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 128.67% since May 17, 2017 and is uptrending. It has outperformed by 117.12% the S&P500.

Analysts await ABIOMED, Inc. (NASDAQ:ABMD) to report earnings on July, 26. They expect $0.80 EPS, up 77.78 % or $0.35 from last year’s $0.45 per share. ABMD’s profit will be $35.50 million for 119.11 P/E if the $0.80 EPS becomes a reality. After $0.80 actual EPS reported by ABIOMED, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 8 analysts covering Abiomed (NASDAQ:ABMD), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Abiomed has $370.0 highest and $220.0 lowest target. $312.75’s average target is -17.95% below currents $381.15 stock price. Abiomed had 12 analyst reports since December 21, 2017 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, December 21. As per Friday, February 2, the company rating was maintained by Morgan Stanley. The company was maintained on Thursday, January 4 by Piper Jaffray. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Buy” rating given on Friday, February 16 by SunTrust. Stephens maintained the shares of ABMD in report on Monday, April 9 with “Buy” rating. The company was maintained on Tuesday, May 1 by Morgan Stanley. The stock has “Buy” rating by Stephens on Friday, February 2. The stock has “Buy” rating by Guggenheim on Friday, February 2. The firm has “Buy” rating given on Thursday, February 1 by Jefferies. The rating was maintained by Piper Jaffray on Thursday, February 1 with “Buy”.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Seekingalpha.com which released: “ABIOMED (ABMD) Q4 2018 Results – Earnings Call Transcript” on May 03, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” published on May 15, 2018, Benzinga.com published: “Abiomed Earnings Outlook” on May 02, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” published on May 11, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” with publication date: May 10, 2018.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $16.91 billion. It also provides continuum of care to heart failure patients. It has a 191.24 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.